Login

Consolidated Balance Sheets

In USD, except per-share amounts
Q3 FY2024
As of Apr 30, 2024
Q4 FY2023
As of Jul 31, 2023
Q3 FY2023
As of Apr 30, 2023
Q1 FY2023
As of Oct 31, 2022
Q3 FY2022
As of Apr 30, 2022
Q3 FY2015
As of Apr 30, 2015
Q2 FY2015
As of Jan 31, 2015
Q1 FY2015
As of Oct 31, 2014
Q4 FY2014
As of Jul 31, 2014
Q3 FY2014
As of Apr 30, 2014
Q2 FY2014
As of Jan 31, 2014
Q1 FY2014
As of Oct 31, 2013
Q4 FY2013
As of Jul 31, 2013
Q3 FY2013
As of Apr 30, 2013
Q2 FY2013
As of Jan 31, 2013
Q1 FY2013
As of Oct 31, 2012
Q3 FY2012
As of Apr 30, 2012
Q2 FY2012
As of Jan 31, 2012
Q1 FY2012
As of Oct 31, 2011
Current assets
Cash
Total current assets
Other assets:
Investment GENBIO
Investments
Intangible assets
Website design
Total other assets
Total assets
Liabilities
Current liabilities
Accounts payable
Accounts payable and accrued expenses
Convertible note payable, net of unamortized discount
Derivative liability
Loan from shareholder
Loan from affiliate
Affiliated Entity
Total loan from affiliate
Loans payable due to non-related parties, net
Total current liabilities
Total liabilities
Stockholders' deficit
Common stock; $0.0001 par value authorized: 1,000,000,000 shares; issued and outstanding 320,705,865 and 186,878,572
Preferred stock Class C; $0.0001 par value authorized: 1,000,000 shares; issued and outstanding 1,000,000 and 1,000,000
Preferred Class A
Preferred Class B
Preferred Class C
Preferred Class C Member
Additional paid-in-capital
Accumulated deficit
Total stockholders' deficit
Total liabilities and stockholders' deficit

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support